[USEFULNESS OF RUPATADINE FOR PRURITUS OF PATIENTS WITH ATOPIC DERMATITIS].
atopic dermatitis
histamine H1 receptor antagonist
post hoc analysis
pruritus
rupatadine
Journal
Arerugi = [Allergy]
ISSN: 0021-4884
Titre abrégé: Arerugi
Pays: Japan
ID NLM: 0241212
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
14
8
2020
Statut:
ppublish
Résumé
Histamine H1 receptor antagonists (antihistamines) are recommended as adjunctive therapy for atopic dermatitis (AD). However, their long-term usefulness and the effect of updosing have not been clarified. To analyzed the long-term usefulness and the effect of updosing of rupatadine, a second generation antihistamine, for patients with AD. Efficacy and safety of rupatadine were evaluated in 66 AD patients, including 50 patients with dose escalation by post hoc analysis of the phase III trial of rupatadine for Japanese patients with pruritus associated with skin diseases. The mean score at baseline total pruritus score (TPS) was 4.682. It decreased to 3.885 at 2 weeks, and 2.376 at 52 weeks by rupatadine administration. The change (of one week after baseline TPS) was significant. Baseline TPS of dose escalation groups, either after 2 weeks or after week 4, were higher than those of 10mg maintenance dose cases, but no significant difference was shown in the change from baseline TPS among the groups at 52 weeks. The occurrence of adverse drug reactions and somnolence were observed in 19.7% and 15.2% of the subjects. These results suggest the long-term usefulness of rupatadine for pruritus in AD.
Sections du résumé
BACKGROUND
BACKGROUND
Histamine H1 receptor antagonists (antihistamines) are recommended as adjunctive therapy for atopic dermatitis (AD). However, their long-term usefulness and the effect of updosing have not been clarified.
PURPOSE
OBJECTIVE
To analyzed the long-term usefulness and the effect of updosing of rupatadine, a second generation antihistamine, for patients with AD.
METHODS
METHODS
Efficacy and safety of rupatadine were evaluated in 66 AD patients, including 50 patients with dose escalation by post hoc analysis of the phase III trial of rupatadine for Japanese patients with pruritus associated with skin diseases.
RESULTS
RESULTS
The mean score at baseline total pruritus score (TPS) was 4.682. It decreased to 3.885 at 2 weeks, and 2.376 at 52 weeks by rupatadine administration. The change (of one week after baseline TPS) was significant. Baseline TPS of dose escalation groups, either after 2 weeks or after week 4, were higher than those of 10mg maintenance dose cases, but no significant difference was shown in the change from baseline TPS among the groups at 52 weeks. The occurrence of adverse drug reactions and somnolence were observed in 19.7% and 15.2% of the subjects.
CONCLUSION
CONCLUSIONS
These results suggest the long-term usefulness of rupatadine for pruritus in AD.
Identifiants
pubmed: 32435018
doi: 10.15036/arerugi.69.174
doi:
Substances chimiques
rupatadine
2AE8M83G3E
Cyproheptadine
2YHB6175DO
Types de publication
Clinical Trial, Phase III
Journal Article
Langues
jpn
Sous-ensembles de citation
IM